The technology sector's semiconductor industry took the reins on Monday and steered both the Nasdaq Composite and S&P 500 Index to fresh all-time highs to kick off the week.
Tech's gains (+1.1%) seemed to come at the expense of overheated cyclical plays, such as energy (-3.4%) and financials (-0.7%), and amid a decline in Treasury rates, with the 10-year yield off 6 basis points to 1.47% (a basis point is one one-hundredth of a percentage point).
"The move in rates is partially in response to some concerns related to the spread of the delta (COVID) variant, which has caused some countries to re-implement restrictions," says Michael Reinking, senior market strategist at the New York Stock Exchange. "This is also hitting oil prices, which briefly traded to a new high earlier before reversing lower." U.S. crude oil futures finished the day off 1.5% to $72.91 per barrel.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Helping lead tech's rally was Nvidia (NVDA, +5.0%), which jumped after fellow semiconductor firm Broadcom (AVGO, +2.3%) backed Nvidia's $40 billion buyout of chip designer Arm. Related names such as Intel (INTC, +2.8%) and Applied Materials (AMAT, +3.5%) followed suit.
The Nasdaq advanced by 1.0% to a record close of 14,500. The S&P 500's 0.2% gain wasn't as robust, but was enough for a new high of 4,290. The Dow Jones Industrial Average retreated, however, declining 0.4% to 34,283.
Other action in the stock market today:
- The small-cap Russell 2000 slipped 0.5% to 2,322.
- Intellia Therapeutics (NTLA) surged 50.2% after the biotech over the weekend reported positive Phase I data for its gene-editing treatment for transthyretin amyloidosis, a genetic liver disorder in which the body builds up abnormal amounts of protein. The treatment, which is being developed with Regeneron Pharmaceuticals (REGN, -1.4%), is the "first-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans," according to an NTLA press release.
- Facebook (FB) jumped 4.2% after a federal judge in the District of Columbia dismissed an antitrust lawsuit brought forth by the Federal Trade Commission (FTC). "The FTC has failed to plead enough facts to plausibly establish a necessary element of all of its Section 2 claims – namely, that Facebook has monopoly power in the market for Personal Social Networking (PSN) Services," read the filing. Today's pop was enough for FB to close above the $1 trillion market-cap level for the first time ever.
- Gold futures edged up 0.2% to settle at $1,780.70 an ounce.
- The CBOE Volatility Index (VIX) rose 0.9% to settle at 15.76.
- Bitcoin prices jumped 6.9% to $34,455.73. (Bitcoin trades 24 hours a day; prices reported here are as of 4 p.m. each trading day.)
Maybe You Don't Need to Choose Between Growth and Value
Should investors bank in a continued resurgence of tech and other growthy names for the rest of 2021, or does value still have gas in the tank?
As we discussed today in our free A Step Ahead e-letter, Capital Group, the name behind American Funds, says you don't necessarily need to choose.
"There can be growing companies that are cheap and cheap companies that grow, so value and growth are not in opposition," says Capital Group equity portfolio manager Martin Romo. "We are in a target-rich environment with opportunities to invest in companies that are rapidly growing as well as classic cyclicals."
The "growing companies that are cheap and cheap companies that grow" he speaks of are better known by just four letters: GARP. That stands for "growth at a reasonable price," and even with the major indexes at or near all-time highs, several companies offer just that: the prospects for breakneck growth, but also valuations that represent discounts to their own historical multiples and/or the stock market's current valuation.
If you want your own portfolio to pack this one-two punch, check out these 11 GARP picks.
Kyle Woodley was long NVDA as of this writing.
-
Humana to Reduce Prior Authorizations for Medicare Advantage Plans in 2026Humana, the second-largest provider of Medicare Advantage Plans, has pledged to streamline the often frustrating Prior Authorization process.
-
July Fed Meeting: Live Updates and CommentaryThe July Fed meeting could be a lively economic event, with Wall Street keyed into what Fed Chair Powell has to say about interest rates and President Trump.
-
The Best Stocks of the CenturyAs we near the 25-year mark, we looked at which stocks have returned the most. Here are the 10 best stocks of the century so far.
-
How the Stock Market Performed in the First 6 Months of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
5 Ways Portfolios Have Been Impacted In Trump's First Six Months in OfficePresident Trump's first six months in office have kept investors on their toes thanks to whipsaw tariff policies and a massive tax cut and spending bill.
-
If You'd Put $1,000 Into Berkshire Hathaway Stock 20 Years Ago, Here's What You'd Have TodayBerkshire Hathaway is a long-time market beater, but the easy money in BRK.B has already been made.
-
Stock Market Today: Nasdaq Hits a New High as Nvidia SoarsA big day for Nvidia boosted the Nasdaq, but bank stocks created headwinds for the S&P 500.
-
If You'd Put $1,000 Into Procter & Gamble Stock 20 Years Ago, Here's What You'd Have TodayProcter & Gamble stock is a dependable dividend grower, but a disappointing long-term holding.
-
Stock Market Today: Stocks Slip Ahead of Big Earnings, Inflation WeekPerhaps uncertainty about tariffs, inflation, interest rates and economic growth can only be answered with earnings.
-
Stock Market Today: Solid Signals Lift Stocks Despite Tariff NoiseMarkets are whistling over the White House in an ongoing display of corporate America's enduring ability to survive and advance.
